- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S2855||MRS 2578||<1 mg/mL||42 mg/mL||<1 mg/mL|
|S1984||Ticlopidine HCl||4 mg/mL||1 mg/mL||1 mg/mL|
|S4637||Prasugrel Hydrochloride||<1 mg/mL||46 mg/mL||9 mg/mL|
|S3737||Cangrelor Tetrasodium||100 mg/mL||2 mg/mL||<1 mg/mL|
|S1258||Prasugrel||<1 mg/mL||30 mg/mL||7 mg/mL|
|S4079||Ticagrelor||<1 mg/mL||100 mg/mL||53 mg/mL|
|S8725||A-804598||<1 mg/mL||63 mg/mL||6 mg/mL|
|S8519||A-317491||<1 mg/mL||100 mg/mL||100 mg/mL|
|S7705||A-438079 HCl||61 mg/mL||61 mg/mL||20 mg/mL|
|S1415||Clopidogrel||78 mg/mL||83 mg/mL||46 mg/mL|
- P2 Receptor Inhibitors (10)
- New P2 Receptor Products
|Catalog No.||Information||Product Use Citations||Product Validations|
MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.
Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.
Prasugrel hydrochloride is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
Cangrelor is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.
Prasugrel is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM.
Effect of antiplatelet drugs on platelet aggregation in healthy individuals. Samples from healthy individuals were preincubated with anti-platelet drugs (n = 3). Curves and columns show mean platelet aggregation and the relationship between platelet aggregation and drug concen-tration. Bars represent standard deviations. *P < 0.05 as compared with platelet aggregation with the same agonist but no drugs added; pairedStudent’s t-test. (A-C) The drugs tested were abciximab (A), ticagrelor (B), and vorapaxar (C).
A-804598 is a selective P2X7R antagonist with high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.
A-317491 is a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors with Ki values of 22 nM and 9 nM for human P2X3 and P2X2/3 receptors.
A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Clopidogrel is an oral, thienopyridine class antiplatelet agent.
(A) HPLC glycan traces of IgG recovered from joint after K/BxN and PBS or B4ST6Fc treatment with or without clopidogrel. (B) Ratios of monosialylated and agalactosylated glycans (S1/G0) from IgG described in (A).